News & Events

The value of our clients' news is directly related to the macro events and trends shaping the life sciences and healthcare industry. To appreciate one, you must fully understand the other.

Tiberend Strategic Advisors invites those interested in our firm and the companies we represent to access our News Feed and register for our Events Calendar.  Doing so, you will be assured to receive actionable information on the companies and trends that are defining the life sciences and healthcare space.

News Feed

     

Events Calendar

Feb 14 2019

StemoniX® Uses microBrain® 3D, a Functional In Vitro Human Neural Model, to Identify Potential Treatment Modalities for Rett Syndrome

Feb 14 2019

Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease

 

Feb 13 2019

Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference

 

Dec 12 2018

KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

Dec 11 2018

KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

 

Nov 28 2018

Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium

 

Nov 13 2018

Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies

Nov 13 2018

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

 

Nov 13 2018

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

 

Nov 13 2018

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

Nov 8 2018

KemPharm, Inc. Reports Third Quarter 2018 Results

 

Nov 8 2018

Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update

 

Nov 8 2018

OncoSec Appoints Robert Ward to its Board of Directors

Nov 8 2018

Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

 

Nov 7 2018

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

 

Nov 6 2018

OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting

Nov 5 2018

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

 

Nov 5 2018

OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data

 

Nov 2 2018

OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

Nov 1 2018

KemPharm to Report Third Quarter 2018 Results

 

Nov 1 2018

Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018

View more client news »